BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33864685)

  • 1. Tofacitinib for the treatment of refractory pyoderma gangrenosum.
    Orfaly VE; Kovalenko I; Tolkachjov SN; Ortega-Loayza AG; Nunley JR
    Clin Exp Dermatol; 2021 Aug; 46(6):1082-1085. PubMed ID: 33864685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for the Treatment of Pyoderma Gangrenosum.
    Kochar B; Herfarth N; Mamie C; Navarini AA; Scharl M; Herfarth HH
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):991-993. PubMed ID: 30404036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
    Gregory MH; Ciorba MA; Deepak P; Christophi GP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
    [No Abstract]   [Full Text] [Related]  

  • 5. The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A.
    Capella GL; Frigerio E; Fracchiolla C; Altomare G
    Scand J Gastroenterol; 1999 Feb; 34(2):220-1. PubMed ID: 10192206
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib in pyoderma gangrenosum - A case series.
    Sathyanarayana VA; Roy D; Nagaraju B; Rao VKR
    Int J Rheum Dis; 2024 Jan; 27(1):e14810. PubMed ID: 37395471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
    Hubbard VG; Friedmann AC; Goldsmith P
    Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
    Duchini G; Itin P; Arnold A
    Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyoderma Gangrenosum: A Review for the Gastroenterologist.
    Plumptre I; Knabel D; Tomecki K
    Inflamm Bowel Dis; 2018 Nov; 24(12):2510-2517. PubMed ID: 29788368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pustular pyoderma gangrenosum.
    Shankar S; Sterling JC; Rytina E
    Clin Exp Dermatol; 2003 Nov; 28(6):600-3. PubMed ID: 14616824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pyoderma gangrenosum: report of 11 cases].
    López de Maturana D; Amaro P; Aranibar L; Segovia L
    Rev Med Chil; 2001 Sep; 129(9):1044-50. PubMed ID: 11725468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient.
    Salmón Olavarría P; Rubio Iturria S; Nantes Castillejo Ó
    Rev Esp Enferm Dig; 2021 Oct; 113(10):733-734. PubMed ID: 33845581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoderma Gangrenosum With Ulcerative Colitis Successfully Treated With Ustekinumab.
    Piqueras-García J; Sahuquillo-Torralba AJ; Torres-Navarro I; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):776-778. PubMed ID: 31151671
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
    Groleau PF; Grossberg AL; Gaspari AA
    Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
    Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
    Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pyoderma gangrenosum: case series].
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Clin Ter; 2007; 158(4):325-9. PubMed ID: 17953284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infliximab for a girl with refractory pyoderma gangrenosum].
    Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyoderma gangrenosum.
    Conrad C; Trüeb RM
    J Dtsch Dermatol Ges; 2005 May; 3(5):334-42. PubMed ID: 16372799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.